







- [11](10)3. Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, et al. Prevalence and treatment of mental disorders, 1990 to 2003. *N Engl J Med*. 2005;352:2515-23.
- [12] Handley SL, Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. *Naunyn Schmiedebergs Arch Pharmacol*. 1984;327:1-5.
- [13] Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. *Pharmacol Biochem Behav*. 1986;24:525-9.
- [14] R. Adnaik, P. Pai, V. Sapakal, N. Naikwade, and C. Magdum, "Anxiolytic activity of *Vitex negundo* linn. in experimental models of anxiety in mice," *International Journal of Green Pharmacy*, vol. 3, no. 3, pp. 243–247, 2009.
- [15] *Neuropharmacology*. 2010 Jan;58(1):62-8. doi: 10.1016/j.neuropharm.2009.06.039. Epub 2009 Jul 7.
- [16] Retrophin (December 2013). "Retrophin Signs U.S. License Agreement for Syntocinon™ Nasal Spray (Oxytocin)".
- [17] Oxytocin: the neuropeptide of love reveals some of its secrets. Lister RG. *Ethologically-based animal models of anxiety disorders*. *Pharmacol Ther*. 1990;46:321-40.

